CEMIP (cell migration inducing hyaluronidase 1) is a multifunctional protein that mediates hyaluronic acid (HA) depolymerization and plays critical roles in cancer metastasis and vascular function. The protein degrades high molecular weight HA through clathrin-mediated endocytosis, producing intermediate-sized fragments that remodel the extracellular matrix 1. CEMIP promotes epithelial-mesenchymal transition (EMT) and enhances tumor cell migration, invasion, and metastatic colonization, particularly in brain metastasis where it is enriched in tumor-derived exosomes 23. The protein facilitates cancer progression through multiple mechanisms including promoting cell proliferation, enabling resistance to cell death, and modulating the tumor microenvironment 3. In vascular smooth muscle cells, CEMIP maintains contractile phenotype by sequestering MLC20 from its phosphatase PP1c, thereby preserving MLC20 phosphorylation and vascular contractility 4. Clinically, CEMIP overexpression correlates with poor prognosis, advanced tumor stage, and reduced survival across multiple cancer types, making it a potential prognostic biomarker 5. Originally identified in nonsyndromic hearing loss, CEMIP has emerged as a therapeutic target for cancer metastasis prevention and treatment 67.